Search results
28 kwi 2021 · In most previous OFS-related clinical studies, an LHRHa was administered as a 1-month regimen (3.75 mg of leuprolide, 3.6 mg of goserelin, or 3.75 mg of triptorelin), and most breast cancer treatment guidelines also recommend 1-month treatment intervals ( 2, 5, 6, 14, 15 ).
5 kwi 2018 · The Panel recognizes that, when proven fertility preservation methods are not feasible, and in the setting of young women with breast cancer, GnRHa may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency.
17 kwi 2018 · Leuprolide is a safe and effective treatment of estrogen receptor–positive premenopausal breast cancer. Data from the SOFT/TEXT trials solidified leuprolide in combination with an aromatase inhibitor as an effective hormonal treatment for premenopausal breast cancer.
14 wrz 2021 · Efficacy of OFS Combined With Adjuvant Chemotherapy for Fertility Preservation in Premenopausal Women With Breast Cancer. Premenopausal women diagnosed with early breast cancer associated with unfavorable clinico-pathological features are candidates for treatment with systemic chemotherapy.
Leuprolide acetate depot administered every 3 months is as efficacious and tolerable as a monthly injection in combination with an aromatase inhibitor for premenopausal patients with hormone receptor-positive breast cancer.
27 kwi 2021 · Introduction. Breast cancer is the most prevalent malignancy among women worldwide, and approximately 75% of patients are hormone receptor-positive (HR+) ( 1 ). HR+ breast cancer is driven by female hormones, which promote cancer cell growth; thus, endocrine treatment is administered as the standard treatment ( 2 ).
4 sty 2019 · The protocol used for FET cycles was standardized and included downregulation with daily subcutaneous leuprolide acetate followed by series of estrogen patches and progesterone supplementation. The protocols were similar for both fresh and frozen cycles between treatment and control groups.
